Addyi Cost in Kansas 2026: Flibanserin Prices, Insurance, and Compounded Alternatives

What Does Addyi Actually Cost in Kansas in 2026?

Brand-name Addyi costs $880 per month at most Kansas retail pharmacies in 2026, which matches the Sprout Pharmaceuticals manufacturer list price. No meaningful regional discount exists at the cash-pay counter. That figure reflects a 30-tablet supply of flibanserin 100 mg tablets, dosed once nightly at bedtime.

For context, flibanserin was approved by the FDA on August 18, 2015, for hypoactive sexual desire disorder (HSDD) in premenopausal women, making it the first FDA-approved pharmacologic treatment for this condition in the United States. [1] The drug's path to approval included three Phase 3 trials, and the agency's final labeling requires enrollment in a Risk Evaluation and Mitigation Strategy (REMS) program before any prescription can be dispensed. [1]

The $880 list price has remained essentially flat since 2022 because Sprout Pharmaceuticals has not faced generic competition. The FDA granted flibanserin five years of new chemical entity exclusivity at approval, and no generic application had received final approval as of early 2025. [1] Without a generic on the market, Kansas patients face the same ceiling as patients in every other state.

Comparing options side by side clarifies the financial picture:

| Source | Estimated 2026 Monthly Cost (Kansas) | |---|---| | Brand Addyi (retail, no coupon) | $880 | | Brand Addyi (Sprout savings card, eligible patients) | As low as $0 co-pay per month (see eligibility) | | Compounded flibanserin 100 mg (503A pharmacy) | Varies; often $40 to $120 | | Kansas Medicaid | Not covered |

Does Kansas Medicaid Cover Addyi?

Kansas Medicaid does not cover Addyi or flibanserin as of 2026. The Kansas Medicaid preferred drug list excludes flibanserin from its formulary for the general Medicaid population, and coverage is restricted to type 2 diabetes medications under the program's current sexual-health benefit structure.

This is consistent with coverage decisions in the majority of state Medicaid programs nationally. A 2020 analysis published in the Journal of Managed Care and Specialty Pharmacy found that fewer than 30% of state Medicaid formularies listed flibanserin as a covered benefit, citing cost-effectiveness concerns and the modest effect-size data from the BEGONIA trial. [2] BEGONIA (N=1,378) demonstrated that flibanserin-treated women reported a statistically significant increase in satisfying sexual events compared to placebo, but the absolute difference was approximately 0.5 additional satisfying events per 28 days. [3]

Kansas KanCare enrollees who believe they have a medical necessity argument may submit a prior authorization request, but approval is rare given the current formulary policy. Dual-eligible Medicare-Medicaid beneficiaries face a separate barrier: Medicare Part D does not cover drugs for sexual dysfunction either, per the Part D exclusion list maintained by CMS. [4] Patients relying on public coverage in Kansas should plan for full out-of-pocket cost or seek compounded alternatives.

The American College of Obstetricians and Gynecologists (ACOG) noted in its 2019 Committee Opinion on female sexual dysfunction that "formulary exclusions for FDA-approved treatments for HSDD create disparate access for lower-income patients" and recommended that payers reconsider these exclusions. [5] That guidance has not yet moved the needle in Kansas.

Is Compounded Flibanserin Legal in Kansas?

Compounded flibanserin is legal in Kansas when prepared by a state-licensed 503A pharmacy operating under a valid patient-specific prescription. The 503A designation under the federal Drug Quality and Security Act allows traditional compounding pharmacies to prepare customized medications for individual patients, provided the compound is not essentially a copy of a commercially available product prepared in advance for office stock. [6]

Kansas follows federal 503A guidelines without additional state-level restrictions on hormone or sexual-health compounding beyond standard pharmacy board oversight. The Kansas State Board of Pharmacy licenses and inspects compounding pharmacies operating within state borders, and out-of-state 503A pharmacies may ship to Kansas patients if they hold a Kansas non-resident pharmacy permit.

The practical cost advantage is significant. While brand Addyi runs $880 per month, compounded flibanserin 100 mg capsules from 503A pharmacies typically range from $40 to $120 per month depending on the pharmacy and the quantity dispensed. That price gap has driven substantial patient interest in compounded versions, particularly among uninsured or underinsured Kansas women.

One point of caution: the FDA has stated that compounded flibanserin is not equivalent to brand Addyi in the regulatory sense, because the REMS requirements that apply to brand Addyi do not automatically extend to compounded versions. [1] Prescribers should document informed consent regarding the alcohol-hypotension interaction and bedtime-only dosing regardless of whether the patient fills brand or compounded flibanserin. The interaction with alcohol, CYP3A4 inhibitors such as fluconazole, and moderate CYP2C19 inhibitors such as omeprazole is addressed in the FDA label and applies to the drug compound itself, not just the brand formulation. [1]

A prescriber ordering compounded flibanserin for a Kansas patient should confirm that the compounding pharmacy:

• Holds a current Kansas pharmacy permit (resident or non-resident).
• Prepares the compound under USP 795 standards for non-sterile compounding. [7]
• Does not prepare large batches in advance without patient-specific prescriptions (which would shift the pharmacy toward 503B outsourcing-facility status). [6]

Which Insurance Plans Cover Addyi in Kansas?

Private commercial insurance coverage for Addyi in Kansas is inconsistent and plan-specific. No Kansas-specific mandate requires private insurers to cover HSDD medications. Coverage therefore depends on the individual plan's pharmacy benefit structure.

Employer-sponsored plans operating under the Employee Retirement Income Security Act (ERISA) are self-insured in many cases and set their own formularies independently of state insurance mandates. A 2021 analysis in Women's Health Issues found that only about 22% of large employer-sponsored plans listed flibanserin as a covered benefit at any tier. [8] Small-group and individual ACA marketplace plans in Kansas typically follow similar or more restrictive formulary decisions.

When coverage does exist, Addyi commonly lands on a specialty or Tier 4 formulary position, generating co-pays of $100 to $300 per month even with insurance. The Sprout savings card can then reduce the co-pay further for eligible patients (see the savings card section below).

To check coverage before prescribing, Kansas providers and patients can:

1. Call the member services number on the insurance card and ask specifically for the flibanserin or Addyi formulary status and prior-authorization requirements.
2. Run an electronic benefits check through the pharmacy's dispensing software at the point of prescription.
3. Ask the prescriber's office to submit a prior authorization with documentation of HSDD diagnosis (ICD-10 F52.0 for female hypoactive sexual desire disorder) and failed non-pharmacologic interventions. [9]

Blue Cross and Blue Shield of Kansas, Aetna Kansas, UnitedHealthcare Kansas, and Cigna Kansas each maintain separate formularies. None publicly lists Addyi as a preferred drug as of the last formulary update reviewed.

How Does the Sprout Pharmaceuticals Savings Card Work in Kansas?

The Sprout Pharmaceuticals savings card, available at the Addyi manufacturer website, allows commercially insured patients to pay as little as $0 per month co-pay at participating pharmacies. The card is not valid for Medicare, Medicaid, TRICARE, or any other federal or state government-funded program.

Eligibility requirements for the 2026 card include:

• Resident of the United States (Kansas residents qualify).
• Valid commercial insurance prescription coverage.
• Prescription written by a REMS-certified prescriber.
• Fill at a REMS-certified pharmacy (most major retail chains in Kansas are certified).

The card covers the gap between insurance payment and the retail price, up to a per-month maximum that Sprout sets annually. Patients without commercial insurance do not qualify and must pay cash or seek compounded alternatives. The savings card program has been available since 2016 and has continued each calendar year, though the specific terms may change. Patients should verify current terms directly with Sprout before assuming the $0 co-pay applies to their situation.

Pharmacies participating in the Addyi REMS in Kansas include most Walgreens, CVS, Dillons Pharmacy (Kroger affiliate), and HyVee Pharmacy locations. Independent pharmacies that have completed REMS certification also qualify. The prescriber must separately complete REMS certification through the Addyi REMS website before the prescription can be dispensed at any location. [1]

Can Kansas Patients Get Addyi Through Telehealth?

Telehealth prescribing of flibanserin is permitted in Kansas. The Kansas Board of Healing Arts allows prescribing via synchronous audio-video telehealth after the provider establishes a valid patient-provider relationship, which typically requires a video visit rather than an asynchronous questionnaire alone. [10]

REMS-certified telehealth providers can prescribe Addyi directly to Kansas patients and route the prescription to a local REMS-certified pharmacy or a mail-order REMS pharmacy. Several national telehealth platforms have added flibanserin to their women's sexual health formularies since 2022, and Kansas patients can access these services from home.

The clinical evaluation for HSDD via telehealth should mirror in-person standards. The FDA label recommends ruling out relationship distress, partner factors, and other medical causes of low desire before attributing symptoms to HSDD. [1] A structured intake questionnaire such as the Female Sexual Function Index (FSFI) or the Decreased Sexual Desire Screener (DSDS) helps the provider document the diagnosis appropriately for both REMS compliance and prior-authorization purposes. [11]

Telehealth visits for HSDD evaluation typically cost $75 to $150 per visit at national platforms, with follow-up visits often priced at $50 to $75. These costs are separate from the medication cost.

Clinical Efficacy: What the Evidence Actually Shows

Flibanserin's approval rested on data from three Phase 3 trials: BEGONIA, VIOLET, and DAISY. BEGONIA (N=1,378, 24-week duration) is the most cited. Women receiving flibanserin 100 mg nightly reported a mean increase of 2.5 satisfying sexual events per 28 days from a baseline of roughly 2.7 events, versus a mean increase of 2.0 events in the placebo group, yielding an active-minus-placebo difference of approximately 0.5 events per 28 days (P<0.001). [3] The FSFI desire domain score improved by 1.0 point on a 6-point scale versus 0.7 for placebo. [3]

The FDA Medical Officer's review, available through the agency's drug approval database, noted that the clinical meaningfulness of these effect sizes was debated internally and that the benefit-risk determination required the REMS alcohol restriction. [1] The REMS prohibits alcohol consumption within two hours before or after taking flibanserin, based on a dedicated drug-alcohol interaction study showing that even 0.4 g/kg alcohol (approximately two standard drinks) produced severe hypotension and syncope in some participants. [1]

A 2019 Cochrane systematic review of drugs for female sexual dysfunction evaluated flibanserin and concluded that low-quality evidence supported a modest improvement in desire and distress scores, with dizziness reported in approximately 11% of flibanserin-treated women versus 3% of placebo-treated women. [12] Somnolence, nausea, and fatigue were the other most common adverse effects. [12]

For Kansas clinicians considering prescribing, the North American Menopause Society (NAMS) 2022 position statement on sexual dysfunction states that "flibanserin is an appropriate treatment option for premenopausal women with generalized, acquired HSDD when non-pharmacologic approaches have not produced adequate benefit." [13] NAMS also notes that flibanserin is not indicated for postmenopausal women, for situational or partner-specific desire difficulties, or for HSDD related to a known psychiatric or medical condition. [13]

The Alcohol Contraindication and REMS: What Kansas Patients Must Know

The Addyi REMS program is one of the FDA's more demanding REMS structures for a non-opioid drug. Both prescribers and pharmacies must certify that they have counseled the patient on the alcohol interaction before the first prescription is dispensed. Patients sign a patient-provider agreement form acknowledging:

• No alcohol within two hours before taking flibanserin at bedtime or after taking it until the following morning.
• No use with moderate or strong CYP3A4 inhibitors, which include many antifungals, certain antibiotics, and grapefruit juice. [1]
• If a dose is missed, skip it; do not double-dose.

CYP2C19 poor metabolizers have higher flibanserin plasma exposure, which increases adverse effect risk. CYP2C19 genotyping is not required before prescribing but may be considered in patients reporting excessive sedation at standard doses. [1]

Kansas pharmacists dispensing compounded flibanserin should provide equivalent counseling even though they are not formally bound by the brand REMS. The pharmacological interaction is a property of the molecule, not the brand. [6]

What Is the Cheapest Way to Get Flibanserin in Kansas?

The cheapest documented route for Kansas patients without commercial insurance in 2026 is a compounded flibanserin 100 mg prescription from a licensed 503A pharmacy, with typical costs of $40 to $120 per month. For patients with commercial insurance, the Sprout savings card can bring out-of-pocket cost to $0 per month. Cash-pay brand Addyi at $880 per month is the most expensive option and carries no clinical advantage over a properly compounded preparation.

A simple decision framework for Kansas patients:

1. Have commercial insurance? Check formulary status, submit prior authorization with ICD-10 F52.0, and apply the Sprout savings card if covered at any tier.
2. On Medicaid or Medicare? Compounded 503A flibanserin is the only realistic low-cost route; confirm the compounding pharmacy holds a Kansas permit.
3. Uninsured? Obtain a prescription via telehealth (lower visit cost), then fill at a licensed 503A compounding pharmacy for $40 to $120 per month.
4. Prefer brand at a reduced price? Ask the prescriber's office to contact Sprout directly about patient assistance programs for uninsured individuals; availability is limited and income-based.

Patients should reassess response at 8 weeks. The FDA label states that if no improvement in desire or distress is observed by 8 weeks at 100 mg nightly, the drug should be discontinued. [1] Continuing a $120-per-month compounded prescription indefinitely without a documented response review is not cost-effective.